NCT02324998View on ClinicalTrials.gov

Study of Olaparib (± Degarelix) Given to Men With Intermediate/High Risk Prostate Cancer Before Prostatectomy

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

May 31, 2019

Study Completion Date

May 31, 2019

Conditions
Prostate Cancer
Interventions
DRUG

Olaparib

PARP Inhibitor

DRUG

Degarelix

Gonadotrophin releasing hormone blocker

Trial Locations (1)

CB2 0QQ

Addenbrooke's Hospital, Cambridge University Hospitals Foundation Trust,, Cambridge

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Cambridge University Hospitals NHS Foundation Trust

OTHER